Rasagiline: a review of its use in the management of Parkinson's disease (Q28239730)

Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat.

Europe PubMed Central

title

Rasagiline: a review of its use in the management of Parkinson's disease (English)

0 references

1 reference

1 reference

3

Caroline M Perry

0 references

Gillian M Keating

series ordinal

2

object named as

Gillian M Keating

0 references

author name string

Vicki Oldfield

series ordinal

1

0 references

language of work or name

English

0 references

publication date

2007

0 references

published in

Drugs

0 references

volume

67

0 references

issue

12

0 references

page(s)

1725-47

0 references

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767120-00006

Occurrence of different cancers in patients with Parkinson's disease

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767120-00006

Clinical applications of MAO-inhibitors

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767120-00006

Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation

21 January 2018

1 reference

12 December 2020

Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease

1 reference

12 December 2020

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

1 reference

12 December 2020

A Prospective Cohort Study of Cancer Incidence Following the Diagnosis of Parkinson's Disease

1 reference

12 December 2020

The therapeutic potential of monoamine oxidase inhibitors

1 reference

12 December 2020

Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004

1 reference

12 December 2020

Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor

1 reference

12 December 2020

Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B.

1 reference

12 December 2020

Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline

1 reference

12 December 2020

Parkinson's disease therapy: tailoring choices for early and late disease, young and old patients

1 reference

12 December 2020

The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo

1 reference

12 December 2020

MAO-B inhibitors for the treatment of Parkinson's disease

1 reference

12 December 2020

Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase

1 reference

12 December 2020

Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa

1 reference

12 December 2020

Safety of rasagiline in elderly patients with Parkinson disease

1 reference

12 December 2020

Low cancer rates among patients with Parkinson's disease

1 reference

12 December 2020

Pharmacology of rasagiline (N-propargyl-1R-aminoindan).

1 reference

12 December 2020

Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.

1 reference

12 December 2020

Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members

1 reference

12 December 2020

Prospects for antiapoptotic drug therapy of neurodegenerative diseases

1 reference

12 December 2020

1 reference

12 December 2020

Early Parkinson's disease: what is the best approach to treatment

1 reference

12 December 2020

Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders

1 reference

12 December 2020

Management of psychotic aspects of Parkinson's disease.

1 reference

12 December 2020

Treatment interventions for Parkinson's disease: an evidence based assessment

1 reference

12 December 2020

Timing of treatment initiation in Parkinson's disease: a need for reappraisal?

1 reference

12 December 2020

Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse.

1 reference

12 December 2020

Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor.

1 reference

12 December 2020

Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal

1 reference

12 December 2020

Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease

1 reference

12 December 2020

Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours

1 reference

12 December 2020

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

1 reference

12 December 2020

In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET.

1 reference

12 December 2020

1 reference

12 December 2020

Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat

1 reference

12 December 2020

Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol

1 reference

12 December 2020

Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells

1 reference

12 December 2020

Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.

1 reference

12 December 2020

Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.

1 reference

12 December 2020

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

1 reference

12 December 2020

Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells

1 reference

12 December 2020

Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat

1 reference

12 December 2020

Rasagiline improves quality of life in patients with early Parkinson's disease

1 reference

12 December 2020

Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model

1 reference

12 December 2020

Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

1 reference

12 December 2020

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

1 reference

12 December 2020

Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats

1 reference

12 December 2020

Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022.

1 reference

12 December 2020

Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan

1 reference

12 December 2020

The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture.

1 reference

12 December 2020

Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model

1 reference

12 December 2020

Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease

1 reference

12 December 2020

Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022

1 reference

12 December 2020

Development and testing of the Parkinson's disease quality of life scale

1 reference

12 December 2020

1 reference

12 December 2020

The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells

1 reference

12 December 2020

Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey.

1 reference

12 December 2020

Pharmacology and neuroprotective properties of rasagiline

1 reference

12 December 2020

Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo

1 reference

12 December 2020

Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline

1 reference

12 December 2020

Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

12 December 2020

An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines

1 reference

12 December 2020

Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients

1 reference

12 December 2020

Neuroprotective strategies in Parkinson's disease : an update on progress

1 reference

12 December 2020

Atypical cancer pattern in patients with Parkinson's disease.

1 reference

12 December 2020

Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline

1 reference

12 December 2020

Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group

1 reference

12 December 2020